

## Chapter 28

# Chinese Herbal Medicine in the Management of Atherosclerosis–Related Chronic Conditions in an Aging Population

**Enoch Chan**

*University of New South Wales, Australia*

**Sai Wang Seto**

*Western Sydney University, Australia*

**Tsoi Ming Au Yeung**

*Hong Kong Community College, Hong Kong*

**Gabriel Hoi Huen Chan**

*Hong Kong Community College, Hong Kong*

### **ABSTRACT**

*Chronic conditions are important problems for an aging society. They impede on healthy aging and increases the cost of living due to increased medical cost. The most prevalent chronic conditions faced by the elderly population are hypertension, high cholesterol and diabetes mellitus. They increase the risk of developing atherosclerosis, a chronic condition which causes heart attack and stroke. This chapter provides a review on existing therapeutics for the treatment of cardiovascular disease, and briefly discusses their side effects. This chapter also provides a brief introduction to Traditional Chinese Medicine (TCM), and its development in ancient China. This will be followed by a discussion on the recent research on the use of Chinese herbal medicine (CHM) in the treatment of cardiovascular diseases, and the potentials and challenges of incorporating CHM in mainstream healthcare system.*

DOI: 10.4018/978-1-5225-7039-4.ch028

## **INTRODUCTION**

Chronic conditions are the major obstacles to healthy aging. They impact on the quality of life and increase the cost of living. The top three most prevalent chronic conditions in the elderly population are hypertension, high cholesterol and diabetes mellitus (Census and Statistics Department Hong Kong SAR, 2014). These chronic conditions are the main contributing factors to atherosclerosis, which can manifest as ischemic heart disease and stroke, the two most common causes of death in the world (World Health Organization, 2014). Chinese Herbal Medicine (CHM) has been used for thousands of years in China. In recent years, there is greater recognition of CHM due to advances in pre-clinical and clinical research leading to mounting evidence of its efficacy.

This chapter will first highlight the important public health problems faced by an aging and westernizing Chinese community – ischemic heart disease and stroke; and an outline of conventional therapeutics being used to manage ischemic heart disease and stroke. Then the pitfalls of existing therapeutics will be discussed, followed by a brief introduction to CHM and generic examples of the use of CHM in health maintenance; and a review on pre-clinical and clinical studies on using CHM or integrative Western and Chinese Medicine specifically in managing ischemic heart disease and stroke. The readers will gain an appreciation of how CHM being combined with modern Western medicine or on its own can be used to manage ischemic heart disease and stroke, and ultimately promoting healthy aging. It also hopes to encourage medical professionals and policymakers to consider how to better engage Chinese medicine practitioners when devising treatment regime for their patients where appropriate to bring about the best outcome for patients.

## **BACKGROUND**

There has been an increasing life expectancy in the populations of most developed countries in the last decade. From 2004 to 2014, life expectancy for both male and female increased by 2 years in most countries including Hong Kong (Food and Health Bureau, 2016). Moreover, in Hong Kong approximately 15% of the population are aged 65 years or older at the end of 2015 (Census and Statistics Department Hong Kong SAR, 2016). It is expected to double and reach approximately 30% in the next 20 years (Census and Statistics Department Hong Kong SAR, 2015), and by then the median age will shift to 50. The increase in life expectancy and the aging of population over the past decades have led to a substantial increase in age-related cardiac, arterial and microvascular diseases in developed countries. It is well documented that aging is closely associated with the progressive decline in normal physiological functions and has significant impact on the heart and vascular system. The incidence of ischemic heart disease and stroke increases exponentially with aging.

According to the World Health Organization (WHO) (2014), ischemic heart disease and stroke were the top two leading causes of death in 2012, accounting for 7.4 million and 6.7 million of deaths, respectively. In Hong Kong, diseases of heart and cerebrovascular diseases were both listed among the top four causes of death in Hong Kong for elderly people aged 65 and over (Census and Statistics Department Hong Kong SAR, 2014).

In a recent study in Hong Kong, total direct medical cost for a patient newly diagnosed with stable ischemic heart disease is approximately HK\$ 89,700 (US\$ 11,500) in the first-year, where the cost can

21 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage:  
[www.igi-global.com/chapter/chinese-herbal-medicine-in-the-management-of-atherosclerosis-related-chronic-conditions-in-an-aging-population/211794](http://www.igi-global.com/chapter/chinese-herbal-medicine-in-the-management-of-atherosclerosis-related-chronic-conditions-in-an-aging-population/211794)

## Related Content

---

### Secondary Metabolites of Carob Tree (*Ceratonia siliqua* L.): Potential Applications

Yassine Mouniane, Yassine Kadmi, Meryem Doubi, Salma Tabi, Issam El-Khadir, Ahmed Chriqui, Abdelaati Soufiani, Brahim El Ouardi, Khawla Rachmoune, Amir Souissi, Arpit Sharma, Shelika Joshi, Mohammed Choukri Belkadi and Driss Hmouni (2025). *Secondary Metabolites and Their Applications in Various Diseases* (pp. 381-408).

[www.irma-international.org/chapter/secondary-metabolites-of-carob-tree-ceratonia-siliqua-l/380582](http://www.irma-international.org/chapter/secondary-metabolites-of-carob-tree-ceratonia-siliqua-l/380582)

### Stress: An Overview

Daniel Opotamutale Ashipala and Anna P. K. Shilunga (2020). *Biopsychosocial Perspectives and Practices for Addressing Communicable and Non-Communicable Diseases* (pp. 135-150).

[www.irma-international.org/chapter/stress/252425](http://www.irma-international.org/chapter/stress/252425)

### Lectin as an Anticancer Therapeutic Agent

Vinuta Mane, Suresh B. Arakera, Shubhangi Pingle and Lucky Thakkar (2022). *Handbook of Research on Natural Products and Their Bioactive Compounds as Cancer Therapeutics* (pp. 384-397).

[www.irma-international.org/chapter/lectin-as-an-anticancer-therapeutic-agent/299811](http://www.irma-international.org/chapter/lectin-as-an-anticancer-therapeutic-agent/299811)

### Health Tourism-Based Destination Marketing

Maide Gürcü and Dilaver Tengilimolu (2018). *Medical Tourism: Breakthroughs in Research and Practice* (pp. 107-131).

[www.irma-international.org/chapter/health-tourism-based-destination-marketing/191482](http://www.irma-international.org/chapter/health-tourism-based-destination-marketing/191482)

### Addressing Blood Sourcing Delays in Medical Emergencies: A Comprehensive Study and Digital Solution Proposal

Vijayshri Nitin Khedkar, Manohar Vitthal Desai, Pranali Gajanan Chavhan and Nitin Gawai (2025). *Modern Digital Approaches to Care Technologies for Individuals With Disabilities* (pp. 167-186).

[www.irma-international.org/chapter/addressing-blood-sourcing-delays-in-medical-emergencies/375257](http://www.irma-international.org/chapter/addressing-blood-sourcing-delays-in-medical-emergencies/375257)